MedTrace Logo

Genetic Determinants of Clindamycin/Rifampin Interaction

NCT03267225 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2022-10-25

No results posted yet for this study

Summary

Main objective- To study the influence of the polymorphisms of nuclear receptor proteins pregnane X receptor (PXR), Liver X receptor alpha (LXRα), and Cytochrome P450 (CYP450) on the clindamycin clearance during clindamycin/rifampin combination therapy.

Secondary objectives To study the influence of these polymorphisms on clindamycin clearance, before combination therapy with rifampin (clindamycin monotherapy) To study the influence of these polymorphisms on CYP450 activity before combination therapy with rifampin (clindamycin monotherapy) To study the influence of these polymorphisms on the increase of CYP450 activity after clindamycin/rifampin combination therapy To study the difference between the expected and observed clindamycin serum concentrations after dosage adjustment, in patients with clindamycin dosage adjustment after combination therapy with rifampin

Conditions

  • VA Drug Interaction

Sponsors & Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

    collaborator NETWORK

  • Dr Valerie ZELLER

    lead OTHER

Principal Investigators

  • Valérie Zeller, MD · GH Diaconesses Croix Saint Simon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2021-04-15
Completion
2021-04-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03267225 on ClinicalTrials.gov